KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Net Income: 2012-2024

Historic Net Income for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to -$248.2 million.

  • Xenon Pharmaceuticals' Net Income fell 44.76% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$320.2 million, marking a year-over-year decrease of 50.05%. This contributed to the annual value of -$248.2 million for FY2024, which is 36.07% down from last year.
  • As of FY2024, Xenon Pharmaceuticals' Net Income stood at -$248.2 million, which was down 36.07% from -$182.4 million recorded in FY2023.
  • Xenon Pharmaceuticals' Net Income's 5-year high stood at -$28.8 million during FY2020, with a 5-year trough of -$248.2 million in FY2024.
  • Over the past 3 years, Xenon Pharmaceuticals' median Net Income value was -$182.4 million (recorded in 2023), while the average stood at -$185.3 million.
  • Its Net Income has fluctuated over the past 5 years, first surged by 30.67% in 2020, then slumped by 173.54% in 2021.
  • Yearly analysis of 5 years shows Xenon Pharmaceuticals' Net Income stood at -$28.8 million in 2020, then slumped by 173.54% to -$78.9 million in 2021, then plummeted by 58.99% to -$125.4 million in 2022, then plummeted by 45.43% to -$182.4 million in 2023, then tumbled by 36.07% to -$248.2 million in 2024.